EMJ Podcast: Insights For Healthcare Professionals

This podcast explores the genetic determinants and mechanisms of breast and ovarian cancer. Jonathan and Sofia Merajver, Michigan Medicine, Ann Arbor, USA, discuss brain metastases, the severity of inflammatory breast cancer, and the movement of cancers through tissue.

Use the following timestamps to navigate this episode!

(00:00)-Introduction

(02:27)-Sofia’s journey into medicine

(04:10)-Personal stakes

(05:09)-Not being your doctor

(06:58)-Genes in inflammatory breast cancer

(10:58)-RHO proteins

(12:52)-Brain metastasis

(17:33)-Crossing the blood–brain barrier

(22:11)-Aggressive phenotypes of breast cancer

(24:18)-Chemoprevention in breast cancer

This podcast explores the mOm Incubator, the importance of collaboration with healthcare professionals when designing medical devices, and the environmental impact of healthcare. Jonathan is joined by James Roberts, co-founder and CEO of mOm Incubators Ltd., a MedTech start-up on a mission to provide global access to high-quality healthcare. The pair discuss how the mOm incubator compares to traditional incubators, and the problems it solves.

 

Use the following timestamps to navigate this episode!

(00:00)-Introduction

(02:11)-Sparking interest in medical innovation

(04:11)-Navigating a medical device start-up

(07:03)-Unveiling the mOm incubator

(10:19)-The value of input from HCPs in device development

(13:04)-Delivering a simple yet low-risk device

(16:14)-Supplying mOm incubators to Ukraine

(20:16)-Considering the environmental impacts of medical devices

(23:30)-James’ proudest achievements

(26:58)-Looking to the future

(28:48)-Transport for London’s map of engineering icons

(31:09)-Three wishes for the future of healthcare

In this bonus episode of the EMJ podcast, Dr. Douglas Bradley is joining our host Dr Hannah Moir to discuss the recent outcomes from the ADVENT-HF randomised clinical trial. The discussion revolves around the relationship between heart failure and co-existing obstructive and/or central sleep apnoea. Dr Bradley considers the use of adaptive servo-ventilation (ASV), a non-invasive positive airway therapy, and provides insights on the trial outcomes. He also delves into the mechanism of action underlying ASV and discusses future developments in the sleep and cardiovascular space.   This podcast has been funded by Philips.

In this final episode of the series, the discussion focuses on the role of therapeutic drug monitoring and current practices, as well as how treatment decisions are made for patients refractory to anti-TNFs. The guests conclude by discussing the future of anti-TNFs and identifying the remaining gaps in the care of patients with inflammatory bowel disease.

This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this penultimate episode of the series on anti-TNFs for inflammatory bowel disease, our expert gastroenterologists discuss treatment options for difficult-to-treat Crohn’s disease and ulcerative colitis, including recent views and decision-making.

This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Expanding the discussion of the use of anti-TNF biosimilars, in this episode, our expert panel provides insights on switching and the handling of adalimumab biosimilars.

This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this episode, our expert gastroenterologists consider the importance of anti-TNF biosimilars as a treatment option for inflammatory bowel disease and the corresponding guideline recommendations.

This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this episode, our experts discuss the use of combination therapy involving anti-TNFs and immunomodulators, with a focus on the synergy and immunogenic effects, clinical trial outcomes, and the conversations that need to be had with patients.

This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Our expert gastroenterologists continue their discussion of the side effects and risks of anti-TNFs, including infection, vaccine immunogenicity, and tuberculosis (TB) risk, as well as monitoring approaches.

This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Our gastroenterology experts consider the patient's underlying comorbidities when making treatment decisions regarding anti-TNFs. They also evaluate the safety profile and risks, particularly for elderly patients

This podcast series has been supported by Viatris, who were not involved in the creation of this content.